AR047568A1 - ENDOPROTESIS COVERED WITH THERAPEUTICALLY ACTIVE PHARMACO. - Google Patents

ENDOPROTESIS COVERED WITH THERAPEUTICALLY ACTIVE PHARMACO.

Info

Publication number
AR047568A1
AR047568A1 ARP040104666A ARP040104666A AR047568A1 AR 047568 A1 AR047568 A1 AR 047568A1 AR P040104666 A ARP040104666 A AR P040104666A AR P040104666 A ARP040104666 A AR P040104666A AR 047568 A1 AR047568 A1 AR 047568A1
Authority
AR
Argentina
Prior art keywords
endoprotesis
pharmaco
covered
therapeutically active
restenosis
Prior art date
Application number
ARP040104666A
Other languages
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR047568A1 publication Critical patent/AR047568A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Liberacion local de un inhibidor de la Janus quinasa 3 (JAK3), en particular desde una endoprotesis intravascular, directamente desde los microporos de la endoprotesis o mezclado o unido a un recubrimiento polimérico aplicado sobre la endoprotesis, para inhibir la proliferacion tisular neoíntima y, por lo tanto, prevenir la reestenosis. También facilita el rendimiento de la endoprotesis en la inhibicion de la reestenosis.Local release of a Janus kinase 3 (JAK3) inhibitor, in particular from an intravascular endoprotesis, directly from the micropores of the endoprotesis or mixed or attached to a polymeric coating applied on the endoprotesis, to inhibit neointimal tissue proliferation and, by Therefore, prevent restenosis. It also facilitates the performance of endoprotesis in the inhibition of restenosis.

ARP040104666A 2003-12-17 2004-12-15 ENDOPROTESIS COVERED WITH THERAPEUTICALLY ACTIVE PHARMACO. AR047568A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53083803P 2003-12-17 2003-12-17

Publications (1)

Publication Number Publication Date
AR047568A1 true AR047568A1 (en) 2006-01-25

Family

ID=34738607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104666A AR047568A1 (en) 2003-12-17 2004-12-15 ENDOPROTESIS COVERED WITH THERAPEUTICALLY ACTIVE PHARMACO.

Country Status (3)

Country Link
AR (1) AR047568A1 (en)
TW (1) TW200522948A (en)
WO (1) WO2005063318A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7713297B2 (en) 1998-04-11 2010-05-11 Boston Scientific Scimed, Inc. Drug-releasing stent with ceramic-containing layer
US20070224235A1 (en) 2006-03-24 2007-09-27 Barron Tenney Medical devices having nanoporous coatings for controlled therapeutic agent delivery
US8187620B2 (en) 2006-03-27 2012-05-29 Boston Scientific Scimed, Inc. Medical devices comprising a porous metal oxide or metal material and a polymer coating for delivering therapeutic agents
US8815275B2 (en) 2006-06-28 2014-08-26 Boston Scientific Scimed, Inc. Coatings for medical devices comprising a therapeutic agent and a metallic material
CA2655793A1 (en) 2006-06-29 2008-01-03 Boston Scientific Limited Medical devices with selective coating
WO2008033711A2 (en) 2006-09-14 2008-03-20 Boston Scientific Limited Medical devices with drug-eluting coating
US7981150B2 (en) 2006-11-09 2011-07-19 Boston Scientific Scimed, Inc. Endoprosthesis with coatings
US8431149B2 (en) 2007-03-01 2013-04-30 Boston Scientific Scimed, Inc. Coated medical devices for abluminal drug delivery
US8070797B2 (en) 2007-03-01 2011-12-06 Boston Scientific Scimed, Inc. Medical device with a porous surface for delivery of a therapeutic agent
US8067054B2 (en) 2007-04-05 2011-11-29 Boston Scientific Scimed, Inc. Stents with ceramic drug reservoir layer and methods of making and using the same
US7976915B2 (en) 2007-05-23 2011-07-12 Boston Scientific Scimed, Inc. Endoprosthesis with select ceramic morphology
US8002823B2 (en) 2007-07-11 2011-08-23 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7942926B2 (en) 2007-07-11 2011-05-17 Boston Scientific Scimed, Inc. Endoprosthesis coating
EP2187988B1 (en) 2007-07-19 2013-08-21 Boston Scientific Limited Endoprosthesis having a non-fouling surface
US7931683B2 (en) 2007-07-27 2011-04-26 Boston Scientific Scimed, Inc. Articles having ceramic coated surfaces
US8815273B2 (en) 2007-07-27 2014-08-26 Boston Scientific Scimed, Inc. Drug eluting medical devices having porous layers
WO2009018340A2 (en) 2007-07-31 2009-02-05 Boston Scientific Scimed, Inc. Medical device coating by laser cladding
EP2185103B1 (en) 2007-08-03 2014-02-12 Boston Scientific Scimed, Inc. Coating for medical device having increased surface area
US8216632B2 (en) 2007-11-02 2012-07-10 Boston Scientific Scimed, Inc. Endoprosthesis coating
US7938855B2 (en) 2007-11-02 2011-05-10 Boston Scientific Scimed, Inc. Deformable underlayer for stent
US8029554B2 (en) 2007-11-02 2011-10-04 Boston Scientific Scimed, Inc. Stent with embedded material
EP2271380B1 (en) 2008-04-22 2013-03-20 Boston Scientific Scimed, Inc. Medical devices having a coating of inorganic material
US8932346B2 (en) 2008-04-24 2015-01-13 Boston Scientific Scimed, Inc. Medical devices having inorganic particle layers
US8231980B2 (en) 2008-12-03 2012-07-31 Boston Scientific Scimed, Inc. Medical implants including iridium oxide
US8071156B2 (en) 2009-03-04 2011-12-06 Boston Scientific Scimed, Inc. Endoprostheses
CN102459270B (en) 2009-04-20 2015-04-29 奥斯拜客斯制药有限公司 Piperidine inhibitors of janus kinase 3
US8287937B2 (en) 2009-04-24 2012-10-16 Boston Scientific Scimed, Inc. Endoprosthese

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors

Also Published As

Publication number Publication date
TW200522948A (en) 2005-07-16
WO2005063318A1 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
AR047568A1 (en) ENDOPROTESIS COVERED WITH THERAPEUTICALLY ACTIVE PHARMACO.
SV2008002477A (en) COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY REF. BHC051038-SV
BRPI0518406A2 (en) compositions having high antiviral and antibacterial efficacy
MXPA04011392A (en) Microbicidal pyrimidine or triazine for preventing sexual hiv transmission.
ES2571779T3 (en) Nicotinamide-based kinase inhibitors
DK1435877T3 (en) Coating of stents to prevent restenosis
CR6682A (en) NON-PEPTIDIC INHIBITORS OF THE VLA-4 DEPENDENT CELL UNION IN THE TREATMENT OF INFLAMMATORY, AUTOIMMUNE AND RESPIRATORY DISEASES
CL2007003594A1 (en) COMPOUNDS DERIVED FROM NITROGEN CONDENSED HETEROCICLES, NON-NUCLEOSIDIC INVERSE TRANSCRIPT INHIBITORS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF AIDS.
WO2007103694A3 (en) Triazine 11-beta hydroxysteroid dehydrogenase type i inhibitors
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
UY28258A1 (en) THERAPEUTIC TREATMENT
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
WO2004014893A3 (en) Antimicrobial aza-bicyclic derivates, their compositions and uses
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
ECSP105178A (en) ARIL UREA COMPOUNDS IN COMBINATION WITH OTHER CITTATIC OR CYTOTOXIC AGENTS FOR CANCER TREATMENT IN HUMANS
TW200716116A (en) Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors
TR200401663T1 (en) The 4-oxoquinoline compound and its use as an HIV integrase inhibitor.
MX2007002236A (en) S-triazolyl -mercaptoacetanildes as inhibitors of hiv reverse transcriptase.
NO20013751L (en) Purine inhibitors of cyclin-dependent kinase 2 and IkB- <alfa>
EA200800006A1 (en) TRIAZOLOPIRIDIN AS AN INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE I
BRPI0400721A (en) Sucralose-containing compositions
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
MXPA03007140A (en) Chemical compounds.
WO2003076398A3 (en) Pyrrole-2, 5-dione derivatives and their use as gsk-3 inhibitors
HUP0400648A2 (en) Compositions for antitumour treatment containing ecteinascidin 743

Legal Events

Date Code Title Description
FB Suspension of granting procedure